National Center for Advancing Translational Sciences; Notice of Closed Meetings, 77853 [2022-27604]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 87, No. 243 / Tuesday, December 20, 2022 / Notices
issues related to implementation of the
National Vaccine Injury Compensation
Program and concerning other matters
as described under section 2119 of the
Public Health Service Act (42 U.S.C.
300aa–19).
Since priorities dictate meeting times,
be advised that start times, end times,
and agenda items are subject to change.
Refer to the ACCV website listed above
for any meeting updates that may occur.
For CY 2023 meetings, agenda items
may include, but are not limited to:
updates from the Division of Injury
Compensation Programs, Department of
Justice, Office of Infectious Disease and
HIV/AIDS Policy (HHS), Immunization
Safety Office (Centers for Disease
Control and Prevention), National
Institute of Allergy and Infectious
Diseases (National Institutes of Health)
and Center for Biologics, Evaluation and
Research (Food and Drug
Administration). Refer to the ACCV
website listed above for all current and
updated information concerning the CY
2023 ACCV meetings, including draft
agendas and meeting materials that will
be posted 5 calendar days before the
meeting.
These meetings are open to the
public. Meetings held by Zoom webinar
will require registration. Registration
details will be provided on the ACCV
website at https://www.hrsa.gov/
advisory-committees/vaccines/
meetings.html. All registrants will be
asked to provide their name, affiliation,
and email address. After registration,
individuals will receive personalized
Zoom information via email.
Members of the public will have the
opportunity to provide comments.
Public participants may submit written
statements in advance of the scheduled
meeting(s). Oral comments will be
honored in the order they are requested
and may be limited as time allows.
Requests to submit a written statement
or make oral comments to the ACCV
should be sent to Pita Gomez using the
contact information above at least 5
business days before the meeting
date(s).
Individuals who need special
assistance or another reasonable
accommodation should notify Pita
Gomez using the contact information
listed above at least 10 business days
before the meeting(s) they wish to
attend. If an in-person meeting is held,
it will occur in a federal government
building, and attendees must go through
a security check to enter the building.
Non-U.S. citizen attendees must notify
HRSA of their planned attendance at
least 20 business days prior to the
meeting in order to facilitate their entry
into the building. All attendees are
VerDate Sep<11>2014
18:41 Dec 19, 2022
Jkt 259001
required to present government-issued
identification prior to entry.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2022–27543 Filed 12–19–22; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Advancing
Translational Sciences; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; CTSA Specialized
Innovation Program.
Date: February 9, 2023.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1037, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Carol (Chang-Sook) Kim,
Ph.D., Scientific Review Administrator,
Office of Grants Management and Scientific
Review, National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1037, Bethesda, MD 20892, (301) 827–7940,
carolko@mail.nih.gov.
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; Rare Disease Review.
Date: February 23, 2023.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1037, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jing Chen, Ph.D., Scientific
Review Officer, Office of Scientific Review,
National Center for Advancing Translational
Sciences, National Institutes of Health, 6701
Democracy Boulevard, Room 1037, Bethesda,
MD 20892, (301) 827–3268, chenjing@
mail.nih.gov.
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
77853
Name of Committee: National Center for
Advancing Translational Sciences Special
Emphasis Panel; CTSA Small Grant Program.
Date: February 24, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1037, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Carol (Chang-Sook) Kim,
Ph.D., Scientific Review Administrator,
Office of Grants Management and Scientific
Review, National Center for Advancing
Translational Sciences, National Institutes of
Health, 6701 Democracy Boulevard, Room
1037, Bethesda, MD 20892, (301) 827–7940,
carolko@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: December 15, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–27604 Filed 12–19–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
[Docket No. DHS–2022–0037]
Homeland Security Advisory Council
The Office of Partnership and
Engagement (OPE), The Department of
Homeland Security (DHS).
ACTION: Notice of charter amendment.
AGENCY:
The Homeland Security
Advisory Council has amended its
charter.
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Rebecca F. Sternhell at HSAC@
hq.dhs.gov or at 202–891–2876.
SUPPLEMENTARY INFORMATION:
The Homeland Security Advisory
Council (HSAC) was established in
April 2003, under the authority of title
6 United States Code, section 451, and
chartered under the provisions of the
Federal Advisory Committee Act
(FACA), 5 U.S.C. app. This
discretionary Council provides
nonpartisan and organizationally
independent strategic advice to the
Secretary of Homeland Security on
critical matters related to Homeland
Security.
The HSAC has made the following
three amendments to its charter.
1. The previous charter stated there
was one Chair. It is now amended to
provide for two co-Chairs and a ViceChair who will support the co-Chairs.
E:\FR\FM\20DEN1.SGM
20DEN1
]]>Agencies
[Federal Register Volume 87, Number 243 (Tuesday, December 20, 2022)]
[Notices]
[Page 77853]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-27604]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Center for Advancing Translational Sciences; Notice of
Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Center for Advancing Translational
Sciences Special Emphasis Panel; CTSA Specialized Innovation
Program.
Date: February 9, 2023.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Center for Advancing Translational Sciences,
National Institutes of Health, 6701 Democracy Boulevard, Room 1037,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Carol (Chang-Sook) Kim, Ph.D., Scientific Review
Administrator, Office of Grants Management and Scientific Review,
National Center for Advancing Translational Sciences, National
Institutes of Health, 6701 Democracy Boulevard, Room 1037, Bethesda,
MD 20892, (301) 827-7940, [email protected].
Name of Committee: National Center for Advancing Translational
Sciences Special Emphasis Panel; Rare Disease Review.
Date: February 23, 2023.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Center for Advancing Translational Sciences,
National Institutes of Health, 6701 Democracy Boulevard, Room 1037,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Jing Chen, Ph.D., Scientific Review Officer,
Office of Scientific Review, National Center for Advancing
Translational Sciences, National Institutes of Health, 6701
Democracy Boulevard, Room 1037, Bethesda, MD 20892, (301) 827-3268,
[email protected].
Name of Committee: National Center for Advancing Translational
Sciences Special Emphasis Panel; CTSA Small Grant Program.
Date: February 24, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Center for Advancing Translational Sciences,
National Institutes of Health, 6701 Democracy Boulevard, Room 1037,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Carol (Chang-Sook) Kim, Ph.D., Scientific Review
Administrator, Office of Grants Management and Scientific Review,
National Center for Advancing Translational Sciences, National
Institutes of Health, 6701 Democracy Boulevard, Room 1037, Bethesda,
MD 20892, (301) 827-7940, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.859,
Pharmacology, Physiology, and Biological Chemistry Research; 93.350,
B--Cooperative Agreements; 93.859, Biomedical Research and Research
Training, National Institutes of Health, HHS)
Dated: December 15, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-27604 Filed 12-19-22; 8:45 am]
BILLING CODE 4140-01-P
